Celon Pharma (CLN) Stock Overview

An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. More details

CLN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for CLN from our risk checks.

CLN Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

Celon Pharma S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Celon Pharma
Historical stock prices
Current Share Pricezł23.05
52 Week Highzł32.90
52 Week Lowzł20.85
Beta0.83
1 Month Change4.30%
3 Month Change-7.06%
1 Year Change-8.53%
3 Year Change38.86%
5 Year Change-44.26%
Change since IPO3.46%

Recent News & Updates

Celon Pharma S.A. (WSE:CLN) Could Be Riskier Than It Looks

Mar 06
Celon Pharma S.A. (WSE:CLN) Could Be Riskier Than It Looks

Recent updates

Celon Pharma S.A. (WSE:CLN) Could Be Riskier Than It Looks

Mar 06
Celon Pharma S.A. (WSE:CLN) Could Be Riskier Than It Looks

Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position

Nov 28
Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Aug 21
A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24
Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Jul 13
Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Nov 04
We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Aug 04
We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

May 23
Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Mar 02
Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09
Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24
Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03
Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Shareholder Returns

CLNPL PharmaceuticalsPL Market
7D-4.2%-3.5%-0.4%
1Y-8.5%-15.8%12.9%

Return vs Industry: CLN exceeded the Polish Pharmaceuticals industry which returned -13.7% over the past year.

Return vs Market: CLN underperformed the Polish Market which returned 13.3% over the past year.

Price Volatility

Is CLN's price volatile compared to industry and market?
CLN volatility
CLN Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement5.3%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.2%

Stable Share Price: CLN has not had significant price volatility in the past 3 months compared to the Polish market.

Volatility Over Time: CLN's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002567Maciej Wieczorekwww.celonpharma.com

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.

Celon Pharma S.A. Fundamentals Summary

How do Celon Pharma's earnings and revenue compare to its market cap?
CLN fundamental statistics
Market capzł1.24b
Earnings (TTM)-zł43.86m
Revenue (TTM)zł215.11m
5.8x
P/S Ratio
-28.3x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLN income statement (TTM)
Revenuezł215.11m
Cost of Revenuezł69.38m
Gross Profitzł145.73m
Other Expenseszł189.59m
Earnings-zł43.86m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin67.75%
Net Profit Margin-20.39%
Debt/Equity Ratio1.1%

How did CLN perform over the long term?

See historical performance and comparison

Dividends

0.3%
Current Dividend Yield
23%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 20:10
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celon Pharma S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Vladimira UrbankovaErste Group Bank AG